IP Verse

Cd19 Specific Chimeric Antigen Receptor And Uses Thereof - EP2997141

The patent EP2997141 was granted to Cellectis on Oct 12, 2022. The application was originally filed on May 12, 2014 under application number EP14723436A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2997141

CELLECTIS
Application Number
EP14723436A
Filing Date
May 12, 2014
Status
Granted And Under Opposition
Sep 9, 2022
Grant Date
Oct 12, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACOPATJul 12, 2023ADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONUS2008131415
INTERNATIONAL-SEARCH-REPORTWO2012129514
OPPOSITIONWO2012099973
OPPOSITIONWO2012129414

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- L. J. N. Cooper ET AL, "Good T cells for bad B cells", BLOOD, US, (20120322), vol. 119, no. 12, doi:10.1182/blood-2011-12-398719, ISSN 0006-4971, pages 2700 - 2702, XP055338012
OPPOSITION- Anonymous , "Mus musculus mRNA for anti-human CD19 monoclonal antibody 4G7 immunoglobulin gamma1 heavy chain (IGHG1 gene)", NUCLEOTIDE, URL: NCBI, XP093124471-
OPPOSITION- Anonymous , "Mus musculus mRNA for anti-human CD19 monoclonal antibody 4G7 immunoglobulin kappa light chain (IGK gene)", NUCLEOTIDE, URL: NCBI, XP093124472-
OPPOSITION- Partow Kebriaei, Susan S Kelly, Pallavi Manuri, Bipulendu Jena, Rineka Jackson, Elizabeth Shpall, Richard Champlin, Laurence Cooper, "Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity", Frontiers in bioscience (Scholar edition), United States, United States , (20120101), page 520, Frontiers in bioscience (Scholar edition), URL: http://www.ncbi.nlm.nih.gov/pubmed/22202074, XP055130773-
OPPOSITION- GRAZYNA LIPOWSKA-BHALLA et al., "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20120422), vol. 61, doi:10.1007/s00262-012-1254-0, ISSN 1432-0851 , page 7, XP035074376
OPPOSITION- Partow Kebriaei, Helen Huls, Bipulendu Jena, Mark Munsell, Rineka Jackson, Dean A. Lee, Perry B. Hackett, Gabriela Rondon, Elizabeth Shpall, Richard E. Champlin, Laurence J.N. Cooper, "Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies", Human Gene Therapy, Mary Ann Liebert, (20120501), vol. 23, no. 5, doi:10.1089/hum.2011.167, ISSN 10430342, pages 444 - 450, XP055130799
OPPOSITION- KÜGLER MARKUS ET AL, "Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS MAR 2009, (20090301), vol. 22, no. 3, doi:10.1093/protein/gzn079, pages 135 - 147, XP002575212
OPPOSITION- LANG PETER, ET AL, "Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts", Blood, American Society of Hematology, US, US , (20040515), vol. 103, no. 10, doi:10.1182/blood-2003-05-1735, ISSN 0006-4971, pages 3982 - 3985, XP002443272
OPPOSITION- Kochenderfer James N.; Wilson Wyndham H.; Janik John E.; Dudley Mark E.; Stetler-Stevenson Maryalice; Feldman Steven A.; Maric Irina; Raffeld Mark; Nathan Debbie-Ann N.; Lanier Brock J.; Morgan Richard A.; Rosenberg Steven A., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, US , (20101118), vol. 116, no. 20, doi:10.1182/blood-2010-04-281931, ISSN 0006-4971, pages 4099 - 4102, XP086511364
OPPOSITION- Bipulendu Jena, Sourindra Maiti, Helen Huls, Harjeet Singh, Dean A. Lee, Richard E. Champlin, Laurence J. N. Cooper, "Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials", PLoS ONE, (20130301), vol. 8, no. 3, doi:10.1371/journal.pone.0057838, pages 1 - 12, XP055122892
OPPOSITION- Satta Alessandro; Mezzanzanica Delia; Turatti Fabio; Canevari Silvana; Figini Mariangela, "Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.", Future oncology, Future Medicine Ltd., UK, UK , (20130401), vol. 9, no. 4, doi:10.2217/fon.12.203, ISSN 1744-8301, pages 527 - 539, XP009177484

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents